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ABBREVIATIONS
A: angiography; US: ultrasonography; EUS: endoscopic
ultrasonography; IUS: intraoperative ultrasonography;
EUS-FNA: endoscopic ultrasonography-guided fine-needle
aspiration; MRI: magnetic resonance imaging; SRS:
octreoscan; CT: computerized tomography; MDCT: mul-
tidetector computerized tomography; PET: positron emis-
sion tomography; PET-CT: PET with computerized tomo-
graphy; ICC: immunocytochemistry; I: insulinoma; G:
gastrinomas; PNET: pancreatic neuroendocrine tumor or
apudoma; NF-PNET: non-functioning PNET; MEN: mul-
tiple endocrine neoplasia; VHL: von Hippel-Lindau disease;
R: review; C: cystic; CE: contrast-enhanced. 
INTRODUCTION
The advent of endoscopic ultrasonography (EUS) or
echoendoscopy (EE) represented a breaking point in the local-
ization and diagnosis of PNETs (1-4) (insulinomas, gastrino-
mas, glucagonomas, non-functioning, etc.) as it provided a
high yield (sensitivity around 90%, specificity at 98%) (5-
10) only second to EUS-FNA (almost 100%) (10-15).
New EUS-related technologies such as contrast media
and elastography have also improved PNET localization
(16-22) with percentages matching those obtained with
EUS-FNA.
A recent paper states that contrast agents (S: 95%) sub-
stantially improve conventional EUS findings (21).
Therefore, diagnostic EUS should be now considered
seriously for PNET assessment (10) in addition to elastog-
raphy, contrast media, both things, or even FNA (22). 
Furthermore, novel imaging techniques other than US
(23), CT (24,25), and MRI (25,26), including PET (FDG
& DOPA) and PET-CT, may be used for the localization
and staging of PNETs, particularly when no primary tumor
has been found (27-32) (Table I).
When CT will not find a PNET, EUS does so in 91% of
cases (34). According to several papers EUS is superior to
MDCT (Multiple Detector Computerized Tomography)
(8,21,33,34).
PET-CT may be a match for Octreoscan (31) for tumors
other than insulinomas, and only PET-CT is superior to
Octreoscan when tumors with a high Ki-67 proliferation
index are considered (32), with sensitivity approaching
100% when it comes to finding a primary tumor and its
related metastases (35-38). 
Once a tumor is precisely located its staging must ensue
in order to decide on its appropriate management (surgical
or otherwise) and to define a prognosis according to
histopathology (Figs. 1 and 2) (39).
We have moved from the classical TNM system to the
WHO histological classification (40):
– Well differentiated: benign, smaller than 2 cm, con-
fined to the pancreas, fewer than 2 mitoses per 10
HPFs, Ki-67 below 2%, and chromogranin A +. No
vascular invasion.
– Uncertain behavior: confined to the pancreas and one
or more of the following: a) larger than 2 cm; b) 2-10
mitoses; c) Ki-67 above 2%; and d) vascular invasion
and perineural permeation.
Diagnostic protocol for pancreatic neuroendocrine tumors (PNETs)
Modesto Varas1, Joan Gornals2, José Luis Prieto3 and Julio Iglesias-García4. Grupo de trabajo de
Ultrasonografía Endoscópica de la SEPD
1Unit of Echoendoscopy. Centro Médico Teknon and Hospital Universitario del Valle Hebrón. Barcelona, Spain. 2Unit of
Endoscopy. Hospital Universitario de Bellvitge. Hospitalet de Llobregat, Barcelona, and Centro Médico Teknon.
Barcelona, Spain. 3Unit of Digestive Diseases. Hospital Punta Europa. Algeciras. Cádiz, Spain. 4Department of Digestive
Diseases. Hospital Clínico Universitario de Santiago de Compostela. A Coruña, Spain
1130-0108/2012/104/1/29-32
REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS
Copyright © 2012 ARÁN EDICIONES, S. L.
REV ESP ENFERM DIG (Madrid)
Vol. 104. N.° 1, pp. 29-32, 2012
Received: 29-04-11.
Accepted: 01-09-11.
Correspondence: Modesto Varas. Unit of Echoendoscopy. Centro Médico
Teknon. Marquesa de Vilallonga, 12. 08017 Barcelona. Spain.
e-mail: varas@dr.teknon.es
POINT OF VIEW
Varas M, Gornals J, Prieto JL, Iglesias-García J. Diagnostic pro-
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Pancreatic tumor with PNET suspicion after US/CT/MRI/EUS: hypoechogenic (5% Q)
Nonresectable, with infiltration or metastasis
(malignant) (CT/PET-CT)
No matastases and resectable (benign?)
EUE-FNA if doubts or NF-NET CT, Octreoscan (85%) or EUS 
with symptoms and positive hormones +
(FUNCTIONING)





No doubtDubious (small, NF, etc.)







Fig. 1. General diagnostic algorithm (modified from reference 22).
Table I. A comparison of PNET detection rates with several imaging techniques
Author             Year                N.º                   % Insulinoma Size CT EUS MR SRS US A PET
Zimmer            1994               18                    88 52
Ueno                1996 (5)          7                      71% 57 100 86 100
Proye                1998               7                      77
Anderson         2000 (6)          54                    58% 15 mm 93 44
Thoeni              2000                                       80
Rickes               2003 (23)        29                    54 94 US-CE
Gouya              2003 (24)        30                    100% 20 mm 72 94
Rappeport        2006 (8)          20                    10% 18 mm 80 100
Koopmans       2008 (29)        23                    87 78 89
Alsohaibani      2008 (9)          14                    4-25 mm 77 100 67 50
                                                                       90 USE-PAAF
Malagò            2009 (42)        38                    0% 81.5 US-CE
An                   2010 (43)        31                    100% 89 US-CE
Ishikawa           2010 (21)        41                    81 95 45
Suzuki              2010 (15)        34                    30 mm 62 65 32
                                                                       90 USE-PAAF
Druce               2010 (26)        30                    100% 64 65 75 50
Versari              2010 (33)        19                    91 100 92
Khashab           2011 (34)        60                    32% 32.7 mm 63 92
Gornals            2011 (14)        9 y 16 casos     33% 19 mm 100 USEPAAF
Varas                2011 (35)        19                   10% 20 mm 88 100 80 83 100
Turuga             2011 (37)        Revisión           80 70 85 100
Tan                   2011 (38)        Revisión           94 80-90 80-90 <70 sólo US 90-100
                                                                       66%
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– Well-differentiated endocrine carcinoma: low malig-
nity. Macroscopic local invasion and/or metastasis
(malignant). No vascular invasion.
– Poorly-differentiated endocrine carcinoma: high
malignity, over 10-20 mitoses per 10 HPFs. Ki-67
above 15-20%. Vascular invasion.
For instance, in a series of 139 NF-PNETs incidentally
identified (mean size: 3 cm) and then operated upon, 19%
were classified as benign, 52% as with uncertain behavior,
and 28% as malignancies. Mean 3-year follow-up of 80%
(112 cases) revealed an actuarial survival of 89, 92.5, and
50%, respectively, at 5 years (44). 
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INSULINOMA: CT + EUS (100%) (24) 
versus CT + MRI (26)
– Isolated insulinoma: enucleation following 
palpation plus IUS
– Multiple insulinoma: pancreatectomy
GASTRINOMA: OCTREOSCAN vs. PET with 
octreotide + EUS
Duodenal endoscopic/surgical transillumination
– Sporadic gastrinoma: resection
– MEN-1: resection if > 2.5 cm
NON-FUNCTIONING: CT + EUS-FNA (1,45)
– Sporadic NFT: resection or surveillance if small 
in size (41)
– MEN-1: resection if > 2 cm
– VHL: resection if > 2-3 cm
REMAINING FUNCTIONING TUMORS: 
CT + Octreoscan + EUS
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